Lyrica Dose Response Study With Restless Legs Syndrome (R... | NCT00676403 | Trialant
NCT00676403
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Status
Completed
Last Update Posted
Feb 10, 2021Actual
Enrollment
137Actual
Phase
Phase 2
Conditions
Restless Legs Syndrome
Interventions
placebo
Pregabalin
Pregabalin
Pregabalin
Pregabalin
Pregabalin
Countries
United States
Austria
Germany
Spain
Protocol Section
Identification Module
NCT ID
NCT00676403
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
A0081183
Secondary IDs
Not provided
Brief Title
Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients
Official Title
Randomized, Double-Blind, 6-Week Study Of Pregabalin In Subjects With Restless Legs Syndrome
Acronym
Not provided
Organization
PfizerINDUSTRY
Status Module
Record Verification Date
Jun 2010
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Apr 2008
Primary Completion Date
Jan 2009Actual
Completion Date
Jan 2009Actual
First Submitted Date
May 8, 2008
First Submission Date that Met QC Criteria
May 12, 2008
First Posted Date
May 13, 2008Estimated
Results Waived
Not provided
Results First Submitted Date
Jan 8, 2010
Results First Submitted that Met QC Criteria
Jan 8, 2010
Results First Posted Date
Feb 4, 2010Estimated
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
Jan 21, 2021
Last Update Posted Date
Feb 10, 2021Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
No
Is FDA Regulated Drug
Not provided
Is FDA Regulated Device
Not provided
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients
Detailed Description
Not provided
Conditions Module
Conditions
Restless Legs Syndrome
Keywords
pregabalin, RLS, efficacy, safety
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
137Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
1
Placebo Comparator
Placebo
Drug: placebo
2
Experimental
investigational treatment
Drug: Pregabalin
3
Experimental
investigational treatment
Drug: Pregabalin
4
Experimental
investigational treatment
Drug: Pregabalin
5
Experimental
investigational treatment
Drug: Pregabalin
6
Experimental
investigational treatment
Drug: Pregabalin
Interventions
Name
Type
Description
Arm Group Labels
Other Names
placebo
Drug
Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
1
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
Baseline, Week 6
Secondary Outcomes
Measure
Description
Time Frame
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Moderate to severe idiopathic RLS
symptoms occur predominantly in the evening
symptoms interfere with sleep onset or maintenance
Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, Garcia-Borreguero D, Miceli J. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010 Jun;11(6):512-9. doi: 10.1016/j.sleep.2010.03.003. Epub 2010 May 13.
See Also Links
Label
URL
To obtain contact information for a study center near you, click here.
Subjects meeting entry criteria with a confirmed diagnosis of Restless Leg Syndrome completed a washout of medications if needed prior to starting a 7-day single-blind placebo run-in to identify and exclude placebo responders and to adapt subjects to take study drug 1-3 hours prior to bedtime. Of 218 subjects screened, 137 subjects entered.
Recruitment Details
Not provided
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
Placebo
Single daily oral dose.
FG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
Baseline Characteristics Module
Baseline Analysis Population Description
Not provided
Outcome Measures Module
Outcome Measures
Adverse Events Module
Frequency Threshold
1.45
More Info Module
Limitations and Caveats
Not provided
Annotation Section
No data available
No data is available for this block.
Document Section
No data available
No data is available for this block.
Derived Section
Miscellaneous Info Module
Version Holder
Jul 10, 2026
Removed Countries
Not provided
Submission Tracking
No data available
No data is available for this block.
Condition Browse Module
MeSH Terms
Intervention Browse Module
MeSH Terms
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Not provided
Primary Purpose
Treatment
Observational Model
Not provided
Time Perspective
Not provided
Masking Info
Masking
Double
Masking Description
Not provided
Who Masked
ParticipantInvestigator
Sugar pill
Pregabalin
Drug
50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
2
Lyrica, PD 0144723; CI-1008
Pregabalin
Drug
100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
3
Lyrica, PD 0144723; CI-1008
Pregabalin
Drug
150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
4
Lyrica, PD 0144723; CI-1008
Pregabalin
Drug
300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
5
Lyrica, PD 0144723; CI-1008
Pregabalin
Drug
450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
6
Lyrica, PD 0144723; CI-1008
Week 6
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep [in minutes]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.
Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.
Baseline,, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
Baseline, Week 1, Week 2, Week 4, Week 6
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.
Week 1, Week 2, Week 4, Week 6
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.
Baseline, Week 6
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.
Baseline, Week 6
Little Rock
Arkansas
72205
United States
Pfizer Investigational Site
San Diego
California
92121
United States
Pfizer Investigational Site
Santa Monica
California
90404
United States
Pfizer Investigational Site
Aurora
Colorado
80012
United States
Pfizer Investigational Site
Brandon
Florida
33511
United States
Pfizer Investigational Site
Macon
Georgia
31201
United States
Pfizer Investigational Site
Louisville
Kentucky
40217
United States
Pfizer Investigational Site
Baton Rouge
Louisiana
70808
United States
Pfizer Investigational Site
Raleigh
North Carolina
27607
United States
Pfizer Investigational Site
Salisbury
North Carolina
28144
United States
Pfizer Investigational Site
Winston-Salem
North Carolina
27103
United States
Pfizer Investigational Site
Oklahoma City
Oklahoma
73112
United States
Pfizer Investigational Site
Dallas
Texas
75231
United States
Pfizer Investigational Site
Alexandria
Virginia
22311
United States
Pfizer Investigational Site
Innsbruck
A-6020
Austria
Pfizer Investigational Site
Vienna
A-1080
Austria
Pfizer Investigational Site
Bad Saarow
15526
Germany
Pfizer Investigational Site
Berlin
10969
Germany
Pfizer Investigational Site
Göttingen
37075
Germany
Pfizer Investigational Site
Mittweida
09648
Germany
Pfizer Investigational Site
München
80331
Germany
Pfizer Investigational Site
Oldenburg
26122
Germany
Pfizer Investigational Site
Schwerin
19053
Germany
Pfizer Investigational Site
Madrid
28036
Spain
FG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
FG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
FG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
FG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
FG00023 subjects
FG00122 subjects
FG00223 subjects
FG00322 subjects
FG00424 subjects
FG00523 subjects
COMPLETED
FG00021 subjects
FG00120 subjects
FG00222 subjects
FG00317 subjects
FG00423 subjects
FG00518 subjects
NOT COMPLETED
FG0002 subjects
FG0012 subjects
FG0021 subjects
FG0035 subjects
FG0041 subjects
FG0055 subjects
Type
Comment
Reasons
Adverse Event
FG0001 subjects
FG0012 subjects
FG0020 subjects
FG0035 subjects
FG0041 subjects
FG0052 subjects
Lost to Follow-up
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Reason Unspecified
FG0001 subjects
FG0010 subjects
FG0021 subjects
FG0030 subjects
FG004
Withdrawal by Subject
FG0000 subjects
FG0010 subjects
FG0020 subjects
FG0030 subjects
FG004
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
Placebo
Single daily oral dose.
BG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
BG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
BG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
BG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
BG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
BG006
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG00023
BG00122
BG00223
BG00322
BG00424
BG00523
BG006137
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Customized
Number
participants
Title
Denominators
Categories
18 - 44 years
Title
Measurements
BG0004
BG0015
BG0027
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00013
BG00113
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Change From Baseline in Restless Leg Syndrome (RLS) International Restless Leg Group Symptom Severity Rating Scale (IRLS) Total Score at Week 6
IRLS: Subject-rated instrument to assess RLS symptom severity and impact on daily living; 10 items yielding 2 subscale scores and 1 global (total) score. Subscale scores: symptom severity (6 items) and impact on daily living (3 items), with item 5 (daytime somnolence due to RLS) loaded equally on both subscales. Global score: calculated from all 10 items. Subscale score ranges: symptom severity 0-24, impact of daily living 0-12; global score range: 0-40. Lower scores reflect lower severity and better quality of life. Change from baseline = score at observation minus score at baseline.
ITT. Baseline statistics were calculated only for subjects who had a non-missing change from baseline at at least one post-baseline visit. Recall period = week prior to assessment.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00021
OG00120
OG00222
OG003
Title
Denominators
Categories
Title
Measurements
OG000-7.73± 1.720
OG001-11.83± 1.771
OG002-11.76± 1.694
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
OG002
OG003
OG004
OG005
Dose response analysis ED 50: dose providing 50% of the maximal effect. Statistics were obtained from three parameter model Y = D + G*exp(B*dose) by bootstrapping 2000 data sets, where D = expected response of saturation (maximal effect), B = related to slope of the dose response mechanism (change in response relative to the change in dose), and D+G = expected response at zero dose.
ED-50: Bootstrap Method
Median Difference (Final Values)
37.3
95
0.1
157.7
Non-convergence for the non-liner model occurred in some bootstrap samples which were not included in summarizing the ED50 distribution or confidence interval.
Secondary
Number of Subjects Responding to Treatment as Assessed by the Clinical Global Impression - Improvement Scale (CGI-I)
Clinical Global Impression - Improvement Scale (CGI-I): 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Number of subjects responding to treatment at Week 6 with respect to dose level. CGI-I Responders = subjects who reported CGI-I scores of very much improved or much improved.
ITT; N=number of subjects in a treatment group; n=number of subjects with a clinical Global Impressions Improvement (CGI-I) rating.
Posted
Number
participants
Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Number of Subjects With Categorical Scores on the Clinical Global Impression - Severity Scale (CGI-S)
CGI-S Scale: 7-point clinician rated scale to assess severity of subject's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected.
ITT; N=number of subjects in a treatment group. LOCF: Last Observation Carried Forward.
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
Secondary
Subjective Sleep Questionnaire (SSQ): Latency Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Latency subscale (time to fall asleep [in minutes]): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Lower score reflects greater ease (shorter time) in falling asleep. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
Secondary
Subjective Sleep Questionnaire: Hours of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Hours of sleep subscale reflects change in hours of sleep from baseline. Numerical rating completed by the subject 30 minutes after waking; recall period is the night before.
ITT; baseline statistics were calculated only for subjects who had a non-missing change from baseline at at least one post-baseline visit.
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Subjective Sleep Questionnaire: Number of Awakenings Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Number of awakenings subscale: numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Fewer awakenings reflect better quality of sleep. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had a non-missing change from baseline in at least one post-baseline visit.
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
Secondary
Subjective Sleep Questionnaire: Total Wake Time After Sleep Onset Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Total wake time after sleep onset subscale (in minutes): numerical rating completed by the subject 30 minutes after waking; recall period is the night before. Reduction = improvement. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had a non-missing change from baseline at at least one post-baseline visit.
Subjective Sleep Questionnaire: Quality of Sleep Subscale; Observed Change From Baseline
Subjective Sleep Questionnaire (SSQ): subject-rated instrument used to assess sleep behavior; measures sleep quantity and quality. Comprised of 5 items yielding 5 subscale scores: latency, hours of sleep, number of awakenings, total wake time after sleep onset, and quality of sleep. Quality of sleep subscale: visual analog scale ranging from 1 (very poor) to 100 (excellent) completed by the subject 30 minutes after waking; recall period is the night before. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Disturbance Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep quantity and quality over the past week; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Disturbance Subscale score (4 items): range 0-100; lower score indicates less disturbance. Change from baseline = score at observation minus score at baseline.
ITT, Baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Snoring Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality over the past week. Comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Snoring Subscale score (1 item): range 0-100, lower score indicates less snoring. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Awaken Short of Breath or With Headache Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week ; comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Awaken Short of Breath or with Headache subscale score range: 0-100; lower score indicates less difficulty. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Adequacy Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Adequacy Subscale score range: 0-100; higher scores indicates greater sleep adequacy. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Somnolence Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Somnolence Subscale score range: 0-100; higher score indicates less somnolence. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline,, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Sleep Quantity Subscale; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Quantity (1 item) subscale score range: 0-24 hours. Change from Baseline in number of hours slept. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline,, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): 6-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Sleep Problems Index I (6 items): composite index score range 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): 9-Item Sleep Problems Index; Observed Change From Baseline
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Composite index scores are sleep problems Index I (6 items) and sleep problems Index II (9 items). 9-Item Sleep Problems Index range: 0-100; lower score indicates fewer sleep problems. Change from baseline = score at observation minus score at baseline.
ITT; baseline statistics were calculated only for subjects who had non-missing change from baseline at at least one post-baseline visit.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Secondary
Medical Outcomes Study - Sleep Scale (MOSS-SS): Optimal Sleep; Observed Cases Summarized by Week
MOS-SS: subject-rated instrument used to assess the key constructs of sleep over the past week; assesses sleep quantity and quality and is comprised 12 items yielding 7 subscale scores and 2 composite index scores. Optimal Sleep subscale is derived from sleep quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours of sleep per night.
ITT
Posted
Number
participants
Week 1, Week 2, Week 4, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
Secondary
Restless Leg Syndrome - Quality of Life Scale (RLS-QoL): Change From Baseline to Week 6
RLS QoL: subject-rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life. Recall period is the month prior to the assessment. Change from baseline = score at observation minus score at baseline.
ITT; N = Subjects who were randomized and received at least one dose of study drug; baseline n = subjects who were randomized and received at least one dose of study drug, and had baseline and post-baseline values.
Posted
Least Squares Mean
Standard Error
scores on scales
Baseline, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Secondary
Medical Outcomes Study Short Form 36 (SF-36): Change From Baseline to Week 6
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Recall period: month prior to the assessment. Change from baseline = score at observation minus score at baseline.
ITT; N = Subjects who were randomized and received at least one dose of study drug; baseline n = subjects who were randomized and received at least one dose of study drug, had baseline and post-baseline values.
Posted
Least Squares Mean
Standard Error
scores on scale
Baseline, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
Secondary
Medical Outcomes Study Short Form 36 (SF-36); Number of Subjects With Self-Evaluated Change in Health Status Scores
Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Self-evaluated change in health status: 5 Likert-type response categories ranging from "much worse now" to much better now." Recall period: month prior to the assessment.
ITT; N = number of subjects in a treatment group.
Posted
Number
participants
Baseline, Week 6
ID
Title
Description
OG000
Placebo
Single daily oral dose.
OG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
OG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
OG003
Pregabalin 150 mg
Time Frame
Not provided
Description
Not provided
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
Placebo
Single daily oral dose.
0
23
13
23
EG001
Pregabalin 50 mg
Single daily 50 mg oral dose.
1
22
9
22
EG002
Pregabalin 100 mg
Single daily 100 mg oral dose. Dose was escalated from 50 mg/day after Day 3.
0
23
12
23
EG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
0
22
15
22
EG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
0
24
17
24
EG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
0
23
19
23
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Gastric cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG0030 affected22 at risk
EG004
Other Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
Thrombocytopenia
Blood and lymphatic system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG0030 affected22 at risk
EG0040 affected24 at risk
EG0050 affected23 at risk
Vertigo
Ear and labyrinth disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Diplopia
Eye disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Abdominal distension
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Abdominal pain upper
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Anal fissure
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Constipation
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Diarrhoea
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Dry mouth
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Flatulence
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Haemorrhoids
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Lip swelling
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Nausea
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Toothache
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Vomiting
Gastrointestinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Chest discomfort
General disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Chills
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Fatigue
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0024 affected23 at risk
EG003
Feeling abnormal
General disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Feeling drunk
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Feeling jittery
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Feeling of relaxation
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Gait disturbance
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Hangover
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Mucosal dryness
General disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Oedema peripheral
General disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Thirst
General disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Bronchitis
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Cystitis
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Fungal infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Gastroenteritis viral
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Influenza
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Kidney infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Lower respiratory tract infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Nasopharyngitis
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Pharyngitis streptococcal
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Respiratory tract infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Sinusitis
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Upper respiratory tract infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Urinary tract infection
Infections and infestations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Aspartate aminotransferase increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Blood creatine phosphokinase increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Blood pressure increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Blood thyroid stimulating hormone increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Creatinine renal clearance increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Mean cell volume increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Transaminases increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Weight increased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
White blood cell count decreased
Investigations
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Hypoglycaemia
Metabolism and nutrition disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Increased appetite
Metabolism and nutrition disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Arthralgia
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Back pain
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Joint swelling
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Muscle spasms
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Muscular weakness
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Pain in extremity
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Tendonitis
Musculoskeletal and connective tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Amnesia
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Depressed level of consciousness
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Disturbance in attention
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Dizziness
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0022 affected23 at risk
EG003
Dyslalia
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Headache
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0003 affected23 at risk
EG0015 affected22 at risk
EG0022 affected23 at risk
EG003
Hypoaesthesia
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Hypokinesia
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Lethargy
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Paraesthesia
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Post-traumatic headache
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Restless legs syndrome
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Sciatica
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Sedation
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0002 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Sinus headache
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Somnolence
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Tunnel vision
Nervous system disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Abnormal dreams
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0003 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Anxiety
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Confusional state
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Depression
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Disorientation
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Elevated mood
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Euphoric mood
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Libido decreased
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Nervousness
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Nightmare
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Restlessness
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Stress
Psychiatric disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Urinary incontinence
Renal and urinary disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Erectile dysfunction
Reproductive system and breast disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Postmenopausal haemorrhage
Reproductive system and breast disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Prostatitis
Reproductive system and breast disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Epistaxis
Respiratory, thoracic and mediastinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0020 affected23 at risk
EG003
Nasal congestion
Respiratory, thoracic and mediastinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Rhinitis allergic
Respiratory, thoracic and mediastinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Snoring
Respiratory, thoracic and mediastinal disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Dry skin
Skin and subcutaneous tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0021 affected23 at risk
EG003
Photosensitivity reaction
Skin and subcutaneous tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Pruritus
Skin and subcutaneous tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0011 affected22 at risk
EG0021 affected23 at risk
EG003
Rash
Skin and subcutaneous tissue disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Tooth extraction
Surgical and medical procedures
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Hot flush
Vascular disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Hypotension
Vascular disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Eyelid oedema
Eye disorders
MedDRA (11.1)
Systematic Assessment
EG0001 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Vision blurred
Eye disorders
MedDRA (11.1)
Systematic Assessment
EG0000 affected23 at risk
EG0010 affected22 at risk
EG0020 affected23 at risk
EG003
Certain Agreements
Are all PI(s) employees of the sponsor?
No
Restriction Type
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Pfizer has the right to review disclosures, requesting a delay of < 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), < 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Point of Contact
Title
Organization
Phone
Extension
Email
Pfizer ClinicalTrials.gov Call Center
Pfizer, Inc.
1-800-718-1021
ClinicalTrials.govCallCenter@pfizer.com
ID
Term
D012148
Restless Legs Syndrome
Ancestor Terms
ID
Term
D009422
Nervous System Diseases
D020919
Sleep Disorders, Intrinsic
D020920
Dyssomnias
D012893
Sleep Wake Disorders
D020447
Parasomnias
D001523
Mental Disorders
Browse Leaves
Not provided
Browse Branches
Not provided
ID
Term
D000073893
Sugars
D000069583
Pregabalin
Ancestor Terms
ID
Term
D002241
Carbohydrates
D005680
gamma-Aminobutyric Acid
D000613
Aminobutyrates
D002087
Butyrates
D000144
Acids, Acyclic
D002264
Carboxylic Acids
D009930
Organic Chemicals
D000596
Amino Acids
D000602
Amino Acids, Peptides, and Proteins
Browse Leaves
Not provided
Browse Branches
Not provided
0 subjects
FG0051 subjects
0 subjects
FG0051 subjects
0 subjects
FG0051 subjects
2
BG0049
BG0053
BG00630
45 - 64 years
Title
Measurements
BG00019
BG00115
BG00216
BG00320
BG00415
BG00519
BG006104
>=65 years
Title
Measurements
BG0000
BG0012
BG0020
BG0030
BG0040
BG0051
BG0063
16
BG00313
BG00419
BG00516
BG00690
Male
BG00010
BG0019
BG0027
BG0039
BG0045
BG0057
BG00647
18
OG00423
OG00520
-16.02
± 1.865
OG004-12.89± 1.713
OG005-16.26± 1.771
Superiority or Other (legacy)
OG000
OG001
OG002
OG003
OG004
OG005
Dose response analysis ED 90: dose providing 90% of the maximal effect. Statistics were obtained from three parameter model Y = D + G*exp(B*dose) by bootstrapping 2000 data sets, where D = expected response of saturation (maximal effect), B = related to slope of the dose response mechanism (change in response relative to the change in dose), and D+G = expected response at zero dose.
ED 90: Bootstrap Method
Median Difference (Final Values)
123.9
95
0.4
523.9
Non-convergence for the non-liner model occurred in some bootstrap samples which were not included in summarizing the ED90 distribution or confidence interval.
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. The repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0983
Mean Difference (Final Values)
-4.10
Standard Error of the Mean
2.472
95
-8.97
0.77
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. The repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0966
Mean Difference (Final Values)
-4.03
Standard Error of the Mean
2.415
95
-8.78
0.73
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. The repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0013
Mean Difference (Final Values)
-8.29
Standard Error of the Mean
2.548
95
-13.31
-3.28
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. The repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0353
Mean Difference (Final Values)
-5.16
Standard Error of the Mean
2.437
95
-9.96
-0.36
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. The repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0006
Mean Difference (Final Values)
-8.53
Standard Error of the Mean
2.469
95
-13.40
-3.67
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 6: Responders (n=21, 20, 22, 18, 23, 20)
Title
Measurements
OG00013
OG00112
OG00215
OG00311
OG00417
OG00518
Week 6: Non-Responders
Title
Measurements
OG0008
OG0018
OG0027
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.8784
95
Superiority or Other (legacy)
OG000
OG002
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.6767
95
Superiority or Other (legacy)
OG000
OG003
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.8955
95
Superiority or Other (legacy)
OG000
OG004
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.9505
95
Superiority or Other (legacy)
OG000
OG005
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0466
95
Superiority or Other (legacy)
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Baseline: Normal, Not at All Ill
Title
Measurements
OG0000
OG0010
OG0020
OG0030
OG0040
OG0050
Baseline: Borderline, Mentally Ill
Title
Measurements
OG0000
OG0010
OG0020
OG003
Baseline: Mildly Ill
Title
Measurements
OG0001
OG0011
OG0022
OG003
Baseline: Moderately Ill
Title
Measurements
OG0006
OG0019
OG0028
OG003
Baseline: Markedly Ill
Title
Measurements
OG0007
OG0018
OG0027
OG003
Baseline: Severely Ill
Title
Measurements
OG0008
OG0013
OG0026
OG003
Baseline: Among the Most Extremely Ill
Title
Measurements
OG0001
OG0011
OG0020
OG003
Week 1: Normal, Not at All Ill
Title
Measurements
OG0001
OG0011
OG0021
OG003
Week 1: Borderline, Mentally Ill
Title
Measurements
OG0000
OG0011
OG0021
OG003
Week 1: Mildly Ill
Title
Measurements
OG0004
OG0016
OG0025
OG003
Week 1: Moderately Ill
Title
Measurements
OG00010
OG0018
OG0025
OG003
Week 1: Markedly Ill
Title
Measurements
OG0004
OG0013
OG0025
OG003
Week 1: Severely Ill
Title
Measurements
OG0004
OG0012
OG0023
OG003
Week 1: Among the Most Extremely Ill
Title
Measurements
OG0000
OG0010
OG0020
OG003
Week 2: Normal, Not at All Ill
Title
Measurements
OG0000
OG0012
OG0021
OG003
Week 2: Borderline, Mentally Ill
Title
Measurements
OG0003
OG0014
OG0022
OG003
Week 2: Mildly Ill
Title
Measurements
OG00010
OG0015
OG0029
OG003
Week 2: Moderately Ill
Title
Measurements
OG0003
OG0015
OG0025
OG003
Week 2: Markedly Ill
Title
Measurements
OG0003
OG0013
OG0024
OG003
Week 2: Severely Ill
Title
Measurements
OG0003
OG0011
OG0021
OG003
Week 2: Among the Most Extremely Ill
Title
Measurements
OG0001
OG0010
OG0020
OG003
Week 4: Normal, Not at All Ill
Title
Measurements
OG0001
OG0012
OG0022
OG003
Week 4: Borderline, Mentally Ill
Title
Measurements
OG0004
OG0012
OG0022
OG003
Week 4: Mildly Ill
Title
Measurements
OG0008
OG0017
OG00211
OG003
Week 4: Moderately Ill
Title
Measurements
OG0004
OG0016
OG0026
OG003
Week 4: Markedly Ill
Title
Measurements
OG0003
OG0012
OG0021
OG003
Week 4: Severely Ill
Title
Measurements
OG0002
OG0012
OG0021
OG003
Week 4: Among the Most Extremely Ill
Title
Measurements
OG0000
OG0010
OG0020
OG003
Week 6: Normal, Not at All Ill
Title
Measurements
OG0001
OG0013
OG0024
OG003
Week 6: Borderline, Mentally Ill
Title
Measurements
OG0003
OG0013
OG0024
OG003
Week 6: Mildly Ill
Title
Measurements
OG00011
OG0016
OG0027
OG003
Week 6: Moderately Ill
Title
Measurements
OG0002
OG0015
OG0025
OG003
Week 6: Markedly Ill
Title
Measurements
OG0002
OG0012
OG0022
OG003
Week 6: Severely Ill
Title
Measurements
OG0002
OG0011
OG0020
OG003
Week 6: Among the Most Extremely Ill
Title
Measurements
OG0000
OG0010
OG0020
OG003
LOCF: Normal
Title
Measurements
OG0001
OG0013
OG0024
OG003
LOCF: Borderline, Mentally Ill
Title
Measurements
OG0003
OG0013
OG0024
OG003
LOCF: Mildly Ill
Title
Measurements
OG00012
OG0016
OG0027
OG003
LOCF: Moderately Ill
Title
Measurements
OG0002
OG0016
OG0025
OG003
LOCF: Markedly Ill
Title
Measurements
OG0002
OG0012
OG0022
OG003
LOCF: Severely Ill
Title
Measurements
OG0002
OG0012
OG0021
OG003
LOCF: Among the Most Extremely Ill
Title
Measurements
OG0001
OG0010
OG0020
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.3876
95
Superiority or Other (legacy)
OG000
OG002
Week 1: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.7959
95
Superiority or Other (legacy)
OG000
OG003
Week 1: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.2032
95
Superiority or Other (legacy)
OG000
OG004
Week 1: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.7032
95
Superiority or Other (legacy)
OG000
OG005
Week 1: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0551
95
Superiority or Other (legacy)
OG000
OG001
Week 2: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.4100
95
Superiority or Other (legacy)
OG000
OG002
Week 2: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.6524
95
Superiority or Other (legacy)
OG000
OG003
Week 2: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.3219
95
Superiority or Other (legacy)
OG000
OG004
Week 2: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.3509
95
Superiority or Other (legacy)
OG000
OG005
Week 2: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0053
95
Superiority or Other (legacy)
OG000
OG001
Week 4: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.9835
95
Superiority or Other (legacy)
OG000
OG002
Week 4: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.6668
95
Superiority or Other (legacy)
OG000
OG003
Week 4: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.2823
95
Superiority or Other (legacy)
OG000
OG004
Week 4: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.5687
95
Superiority or Other (legacy)
OG000
OG005
Week 4: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0043
95
Superiority or Other (legacy)
OG000
OG001
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.8662
95
Superiority or Other (legacy)
OG000
OG002
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.3656
95
Superiority or Other (legacy)
OG000
OG003
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0806
95
Superiority or Other (legacy)
OG000
OG004
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.5381
95
Superiority or Other (legacy)
OG000
OG005
Week 6: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0090
95
Superiority or Other (legacy)
OG000
OG001
Last Observation Carried Forward: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.9748
95
Superiority or Other (legacy)
OG000
OG002
Last Observation Carried Forward: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.3936
95
Superiority or Other (legacy)
OG000
OG003
Last Observation Carried Forward: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.1563
95
Superiority or Other (legacy)
OG000
OG004
Last Observation Carried Forward: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.6357
95
Superiority or Other (legacy)
OG000
OG005
Last Observation Carried Forward: Cochran-Mantel-Haenszel test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0133
95
Superiority or Other (legacy)
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-9.8± 5.60
OG001-16.3± 5.76
OG002-13.2± 5.60
OG003-10.4± 5.76
OG004-9.1± 5.65
OG005-20.2± 5.62
Week 2
Title
Measurements
OG000-8.9± 5.60
OG001-20.7± 5.84
OG002-17.2± 5.65
OG003
Week 3
Title
Measurements
OG000-14.6± 5.71
OG001-18.9± 5.90
OG002-13.1± 5.60
OG003
Week 4
Title
Measurements
OG000-13.6± 5.66
OG001-20.4± 5.90
OG002-20.4± 5.60
OG003
Week 5
Title
Measurements
OG000-15.9± 5.71
OG001-26.8± 5.90
OG002-17.6± 5.60
OG003
Week 6
Title
Measurements
OG000-12.4± 5.71
OG001-25.4± 5.90
OG002-19.5± 5.65
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4133
Mean Difference (Final Values)
-6.6
Standard Error of the Mean
8.05
95
-22.4
9.3
Superiority or Other (legacy)
OG000
OG002
Week 1: Conrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6676
Mean Difference (Final Values)
-3.4
Standard Error of the Mean
7.92
95
-19.0
12.2
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9355
Mean Difference (Final Values)
-0.7
Standard Error of the Mean
8.04
95
-16.5
15.2
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9355
Mean Difference (Final Values)
0.6
Standard Error of the Mean
7.97
95
-15.1
16.4
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1895
Mean Difference (Final Values)
-10.5
Standard Error of the Mean
7.94
95
-26.1
5.2
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1443
Mean Difference (Final Values)
-11.9
Standard Error of the Mean
8.10
95
-27.8
4.1
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2946
Mean Difference (Final Values)
-8.4
Standard Error of the Mean
7.96
95
-24.0
7.3
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3686
Mean Difference (Final Values)
-7.4
Standard Error of the Mean
8.22
95
-23.6
8.8
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6079
Mean Difference (Final Values)
-4.1
Standard Error of the Mean
8.02
95
-19.9
11.7
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0016
Mean Difference (Final Values)
-25.5
Standard Error of the Mean
7.99
95
-41.2
-9.7
Superiority or Other (legacy)
OG000
OG001
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5976
Mean Difference (Final Values)
-4.3
Standard Error of the Mean
8.22
95
-20.5
11.8
Superiority or Other (legacy)
OG000
OG002
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8527
Mean Difference (Final Values)
1.5
Standard Error of the Mean
8.00
95
-14.3
17.3
Superiority or Other (legacy)
OG000
OG003
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6973
Mean Difference (Final Values)
-3.2
Standard Error of the Mean
8.29
95
-19.6
13.1
Superiority or Other (legacy)
OG000
OG004
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6895
Mean Difference (Final Values)
-3.2
Standard Error of the Mean
8.09
95
-19.2
12.7
Superiority or Other (legacy)
OG000
OG005
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0209
Mean Difference (Final Values)
-19.1
Standard Error of the Mean
8.21
95
-35.2
-2.9
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4084
Mean Difference (Final Values)
-6.8
Standard Error of the Mean
8.18
95
-22.9
9.3
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3958
Mean Difference (Final Values)
-6.8
Standard Error of the Mean
7.96
95
-22.5
8.9
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5776
Mean Difference (Final Values)
-4.6
Standard Error of the Mean
8.25
95
-20.9
11.7
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5665
Mean Difference (Final Values)
-4.6
Standard Error of the Mean
8.06
95
-20.5
11.3
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0041
Mean Difference (Final Values)
-23.5
Standard Error of the Mean
8.13
95
-39.6
-7.5
Superiority or Other (legacy)
OG000
OG001
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1842
Mean Difference (Final Values)
-10.9
Standard Error of the Mean
8.22
95
-27.1
5.2
Superiority or Other (legacy)
OG000
OG002
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8269
Mean Difference (Final Values)
-1.8
Standard Error of the Mean
8.00
95
-17.5
14.0
Superiority or Other (legacy)
OG000
OG003
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3319
Mean Difference (Final Values)
-8.1
Standard Error of the Mean
8.34
95
-24.5
8.3
Superiority or Other (legacy)
OG000
OG004
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7552
Mean Difference (Final Values)
2.5
Standard Error of the Mean
8.09
95
-13.4
18.5
Superiority or Other (legacy)
OG000
OG005
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0137
Mean Difference (Final Values)
-20.3
Standard Error of the Mean
8.16
95
-36.3
-4.2
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1157
Mean Difference (Final Values)
-13.0
Standard Error of the Mean
8.22
95
-29.2
3.2
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3791
Mean Difference (Final Values)
-7.1
Standard Error of the Mean
8.04
95
-22.9
8.7
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1329
Mean Difference (Final Values)
-12.7
Standard Error of the Mean
8.39
95
-29.2
3.9
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7723
Mean Difference (Final Values)
2.3
Standard Error of the Mean
8.09
95
-13.6
18.3
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score was included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0063
Mean Difference (Final Values)
-22.5
Standard Error of the Mean
8.16
95
-38.6
-6.4
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG0000.23± 0.177
OG0010.57± 0.183
OG0020.29± 0.177
OG0030.55± 0.182
OG0040.45± 0.177
OG0050.72± 0.178
Week 2
Title
Measurements
OG0000.36± 0.177
OG0010.65± 0.186
OG0020.52± 0.179
OG003
Week 3
Title
Measurements
OG0000.36± 0.182
OG0010.61± 0.188
OG0020.53± 0.177
OG003
Week 4
Title
Measurements
OG0000.27± 0.180
OG0010.81± 0.188
OG0020.46± 0.177
OG003
Week 5
Title
Measurements
OG0000.37± 0.182
OG0011.03± 0.188
OG0020.43± 0.177
OG003
Week 6
Title
Measurements
OG0000.19± 0.182
OG0010.84± 0.188
OG0020.42± 0.179
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1715
Mean Difference (Final Values)
0.35
Standard Error of the Mean
0.254
95
-0.15
0.85
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7944
Mean Difference (Final Values)
0.07
Standard Error of the Mean
0.251
95
-0.43
0.56
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1994
Mean Difference (Final Values)
0.33
Standard Error of the Mean
0.255
95
-0.17
0.83
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3652
Mean Difference (Final Values)
0.23
Standard Error of the Mean
0.251
95
-0.27
0.72
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0481
Mean Difference (Final Values)
0.50
Standard Error of the Mean
0.251
95
0.00
0.99
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2501
Mean Difference (Final Values)
0.30
Standard Error of the Mean
0.256
95
-0.21
0.80
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5191
Mean Difference (Final Values)
0.16
Standard Error of the Mean
0.252
95
-0.33
0.66
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0817
Mean Difference (Final Values)
0.46
Standard Error of the Mean
0.262
95
-0.06
0.97
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1146
Mean Difference (Final Values)
0.40
Standard Error of the Mean
0.253
95
-0.10
0.90
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0054
Mean Difference (Final Values)
0.71
Standard Error of the Mean
0.253
95
0.21
1.21
Superiority or Other (legacy)
OG000
OG001
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3389
Mean Difference (Final Values)
0.25
Standard Error of the Mean
0.261
95
-0.26
0.76
Superiority or Other (legacy)
OG000
OG002
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5079
Mean Difference (Final Values)
0.17
Standard Error of the Mean
0.254
95
-0.33
0.67
Superiority or Other (legacy)
OG000
OG003
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0453
Mean Difference (Final Values)
0.53
Standard Error of the Mean
0.265
95
0.01
1.05
Superiority or Other (legacy)
OG000
OG004
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1622
Mean Difference (Final Values)
0.36
Standard Error of the Mean
0.256
95
-0.15
0.86
Superiority or Other (legacy)
OG000
OG005
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0003
Mean Difference (Final Values)
0.96
Standard Error of the Mean
0.262
95
0.45
1.48
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0383
Mean Difference (Final Values)
0.54
Standard Error of the Mean
0.260
95
0.03
1.05
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4495
Mean Difference (Final Values)
0.19
Standard Error of the Mean
0.253
95
-0.31
0.69
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0135
Mean Difference (Final Values)
0.65
Standard Error of the Mean
0.263
95
0.14
1.17
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1423
Mean Difference (Final Values)
0.37
Standard Error of the Mean
0.254
95
-0.13
0.87
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0035
Mean Difference (Final Values)
0.76
Standard Error of the Mean
0.259
95
0.25
1.27
Superiority or Other (legacy)
OG000
OG001
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0125
Mean Difference (Final Values)
0.66
Standard Error of the Mean
0.261
95
0.14
1.17
Superiority or Other (legacy)
OG000
OG002
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8021
Mean Difference (Final Values)
0.06
Standard Error of the Mean
0.254
95
-0.44
0.56
Superiority or Other (legacy)
OG000
OG003
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0249
Mean Difference (Final Values)
0.60
Standard Error of the Mean
0.267
95
0.08
1.13
Superiority or Other (legacy)
OG000
OG004
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3383
Mean Difference (Final Values)
0.25
Standard Error of the Mean
0.256
95
-0.26
0.75
Superiority or Other (legacy)
OG000
OG005
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0001
Mean Difference (Final Values)
1.06
Standard Error of the Mean
0.260
95
0.55
1.57
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0133
Mean Difference (Final Values)
0.65
Standard Error of the Mean
0.261
95
0.14
1.17
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3820
Mean Difference (Final Values)
0.22
Standard Error of the Mean
0.256
95
-0.28
0.73
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0053
Mean Difference (Final Values)
0.75
Standard Error of the Mean
0.269
95
0.23
1.28
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3258
Mean Difference (Final Values)
0.25
Standard Error of the Mean
0.256
95
-0.25
0.76
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0005
Mean Difference (Final Values)
0.92
Standard Error of the Mean
0.260
95
0.41
1.43
Superiority or Other (legacy)
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-0.5± 0.21
OG001-0.9± 0.21
OG002-1.0± 0.21
OG003-1.2± 0.21
OG004-0.7± 0.21
OG005-0.8± 0.21
Week 2
Title
Measurements
OG000-0.7± 0.21
OG001-1.0± 0.22
OG002-1.3± 0.21
OG003
Week 3
Title
Measurements
OG000-0.7± 0.21
OG001-1.0± 0.22
OG002-1.0± 0.21
OG003
Week 4
Title
Measurements
OG000-0.9± 0.21
OG001-1.1± 0.22
OG002-1.2± 0.21
OG003
Week 5
Title
Measurements
OG000-0.8± 0.21
OG001-1.3± 0.22
OG002-1.0± 0.21
OG003
Week 6
Title
Measurements
OG000-1.0± 0.21
OG001-1.0± 0.22
OG002-1.1± 0.21
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1429
Mean Difference (Final Values)
-0.4
Standard Error of the Mean
0.30
95
-1.0
0.1
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0547
Mean Difference (Final Values)
-0.6
Standard Error of the Mean
0.30
95
-1.2
0.0
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0095
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
0.30
95
-1.4
-0.2
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3676
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2959
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3435
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0895
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.30
95
-1.1
0.1
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0844
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.31
95
-1.1
0.1
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0675
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.30
95
-1.1
0.0
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2250
Mean Difference (Final Values)
-0.4
Standard Error of the Mean
0.30
95
-1.0
0.2
Superiority or Other (legacy)
OG000
OG001
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3728
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.31
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG002
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2686
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG003
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0753
Mean Difference (Final Values)
-0.6
Standard Error of the Mean
0.31
95
-1.2
0.1
Superiority or Other (legacy)
OG000
OG004
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1335
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.30
95
-1.0
0.1
Superiority or Other (legacy)
OG000
OG005
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0220
Mean Difference (Final Values)
-0.7
Standard Error of the Mean
0.31
95
-1.3
-0.1
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5754
Mean Difference (Final Values)
-0.2
Standard Error of the Mean
0.31
95
-0.8
0.4
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3480
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0554
Mean Difference (Final Values)
-0.6
Standard Error of the Mean
0.31
95
-1.2
0.0
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4362
Mean Difference (Final Values)
-0.2
Standard Error of the Mean
0.30
95
-0.8
0.4
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3631
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.30
95
-0.9
0.3
Superiority or Other (legacy)
OG000
OG001
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1152
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.31
95
-1.1
0.1
Superiority or Other (legacy)
OG000
OG002
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4741
Mean Difference (Final Values)
-0.2
Standard Error of the Mean
0.30
95
-0.8
0.4
Superiority or Other (legacy)
OG000
OG003
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0091
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
0.31
95
-1.4
-0.2
Superiority or Other (legacy)
OG000
OG004
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1721
Mean Difference (Final Values)
-0.4
Standard Error of the Mean
0.30
95
-1.0
0.2
Superiority or Other (legacy)
OG000
OG005
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0262
Mean Difference (Final Values)
-0.7
Standard Error of the Mean
0.31
95
-1.3
-0.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9505
Mean Difference (Final Values)
0.0
Standard Error of the Mean
0.31
95
-0.6
0.6
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6877
Mean Difference (Final Values)
-0.1
Standard Error of the Mean
0.30
95
-0.7
0.5
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1271
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
0.31
95
-1.1
0.1
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9136
Mean Difference (Final Values)
-0.0
Standard Error of the Mean
0.30
95
-0.6
0.6
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4072
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
0.31
95
-0.9
0.3
Superiority or Other (legacy)
OG005
Pregablin 450 mg/Day
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-23.8± 7.44
OG001-37.9± 7.66
OG002-28.5± 7.47
OG003-29.0± 7.81
OG004-32.2± 7.58
OG005-32.6± 7.46
Week 2
Title
Measurements
OG000-29.5± 7.44
OG001-47.0± 7.79
OG002-36.5± 7.55
OG003
Week 3
Title
Measurements
OG000-34.3± 7.62
OG001-51.4± 8.01
OG002-32.0± 7.47
OG003
Week 4
Title
Measurements
OG000-30.4± 7.53
OG001-50.7± 8.01
OG002-36.5± 7.47
OG003
Week 5
Title
Measurements
OG000-28.7± 7.62
OG001-55.4± 8.01
OG002-30.7± 7.47
OG003
Week 6
Title
Measurements
OG000-34.2± 7.62
OG001-57.0± 7.90
OG002-34.2± 7.55
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1860
Mean Difference (Final Values)
-14.2
Standard Error of the Mean
10.68
95
-35.2
6.9
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6530
Mean Difference (Final Values)
-4.7
Standard Error of the Mean
10.54
95
-25.5
16.0
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6263
Mean Difference (Final Values)
-5.3
Standard Error of the Mean
10.79
95
-26.5
16.0
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4266
Mean Difference (Final Values)
-8.5
Standard Error of the Mean
10.63
95
-29.4
12.5
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4023
Mean Difference (Final Values)
-8.8
Standard Error of the Mean
10.54
95
-29.6
11.9
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1041
Mean Difference (Final Values)
-17.6
Standard Error of the Mean
10.77
95
-38.8
3.6
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5084
Mean Difference (Final Values)
-7.0
Standard Error of the Mean
10.60
95
-27.9
13.8
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2620
Mean Difference (Final Values)
-12.5
Standard Error of the Mean
11.10
95
-34.3
9.4
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3347
Mean Difference (Final Values)
-10.3
Standard Error of the Mean
10.70
95
-31.4
10.7
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1142
Mean Difference (Final Values)
-16.8
Standard Error of the Mean
10.61
95
-37.7
4.1
Superiority or Other (legacy)
OG000
OG001
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1237
Mean Difference (Final Values)
-17.1
Standard Error of the Mean
11.06
95
-38.8
4.7
Superiority or Other (legacy)
OG000
OG002
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8302
Mean Difference (Final Values)
2.3
Standard Error of the Mean
10.67
95
-18.7
23.3
Superiority or Other (legacy)
OG000
OG003
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3039
Mean Difference (Final Values)
-11.6
Standard Error of the Mean
11.22
95
-33.6
10.5
Superiority or Other (legacy)
OG000
OG004
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4595
Mean Difference (Final Values)
-8.0
Standard Error of the Mean
10.77
95
-29.2
13.2
Superiority or Other (legacy)
OG000
OG005
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4338
Mean Difference (Final Values)
-8.6
Standard Error of the Mean
10.97
95
-30.2
13.0
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0647
Mean Difference (Final Values)
-20.4
Standard Error of the Mean
10.99
95
-42.0
1.2
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5651
Mean Difference (Final Values)
-6.1
Standard Error of the Mean
10.61
95
-27.0
14.8
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1634
Mean Difference (Final Values)
-15.6
Standard Error of the Mean
11.16
95
-37.6
6.4
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2209
Mean Difference (Final Values)
-13.2
Standard Error of the Mean
10.77
95
-34.4
8.0
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1293
Mean Difference (Final Values)
-16.5
Standard Error of the Mean
10.84
95
-37.8
4.8
Superiority or Other (legacy)
OG000
OG001
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0161
Mean Difference (Final Values)
-26.8
Standard Error of the Mean
11.06
95
-48.5
-5.0
Superiority or Other (legacy)
OG000
OG002
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8506
Mean Difference (Final Values)
-2.0
Standard Error of the Mean
10.67
95
-23.0
19.0
Superiority or Other (legacy)
OG000
OG003
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0067
Mean Difference (Final Values)
-30.9
Standard Error of the Mean
11.31
95
-53.2
-8.6
Superiority or Other (legacy)
OG000
OG004
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1997
Mean Difference (Final Values)
-13.8
Standard Error of the Mean
10.76
95
-35.0
7.4
Superiority or Other (legacy)
OG000
OG005
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0159
Mean Difference (Final Values)
-26.4
Standard Error of the Mean
10.90
95
-47.9
-5.0
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0388
Mean Difference (Final Values)
-22.8
Standard Error of the Mean
10.98
95
-44.4
-1.2
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9962
Mean Difference (Final Values)
-0.1
Standard Error of the Mean
10.73
95
-21.2
21.1
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0839
Mean Difference (Final Values)
-19.8
Standard Error of the Mean
11.41
95
-42.3
2.7
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5216
Mean Difference (Final Values)
-6.9
Standard Error of the Mean
10.83
95
-28.3
14.4
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0534
Mean Difference (Final Values)
-21.3
Standard Error of the Mean
10.98
95
-42.9
0.3
Superiority or Other (legacy)
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG0005.0± 4.10
OG00118.8± 4.21
OG00215.2± 4.10
OG00315.9± 4.23
OG00411.5± 4.16
OG00517.2± 4.11
Week 2
Title
Measurements
OG00011.3± 4.10
OG00123.3± 4.27
OG00218.7± 4.13
OG003
Week 3
Title
Measurements
OG00013.8± 4.17
OG00123.0± 4.31
OG00218.6± 4.10
OG003
Week 4
Title
Measurements
OG00013.2± 4.14
OG00123.8± 4.31
OG00222.0± 4.10
OG003
Week 5
Title
Measurements
OG00014.7± 4.17
OG00128.7± 4.31
OG00219.9± 4.10
OG003
Week 6
Title
Measurements
OG00013.9± 4.17
OG00127.6± 4.31
OG00223.5± 4.14
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0199
Mean Difference (Final Values)
13.8
Standard Error of the Mean
5.89
95
2.2
25.4
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0768
Mean Difference (Final Values)
10.3
Standard Error of the Mean
5.78
95
-1.1
21.7
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0642
Mean Difference (Final Values)
11.0
Standard Error of the Mean
5.91
95
-0.7
22.6
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2643
Median Difference (Final Values)
6.6
Standard Error of the Mean
5.88
95
-5.0
18.2
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0358
Mean Difference (Final Values)
12.2
Standard Error of the Mean
5.80
95
0.8
23.7
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0428
Mean Difference (Final Values)
12.1
Standard Error of the Mean
5.93
95
0.4
23.8
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1993
Mean Difference (Final Values)
7.5
Standard Error of the Mean
5.81
95
-4.0
18.9
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0331
Mean Difference (Final Values)
12.9
Standard Error of the Mean
6.04
95
1.1
24.8
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0415
Mean Difference (Final Values)
12.1
Standard Error of the Mean
5.91
95
0.5
23.8
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0295
Mean Difference (Final Values)
12.8
Standard Error of the Mean
5.83
95
1.3
24.3
Superiority or Other (legacy)
OG000
OG001
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1267
Mean Difference (Final Values)
9.2
Standard Error of the Mean
6.01
95
-2.6
21.1
Superiority or Other (legacy)
OG000
OG002
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4175
Mean Difference (Final Values)
4.7
Standard Error of the Mean
5.84
95
-6.8
16.2
Superiority or Other (legacy)
OG000
OG003
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0342
Mean Difference (Final Values)
13.0
Standard Error of the Mean
6.09
95
1.0
25.0
Superiority or Other (legacy)
OG000
OG004
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1038
Mean Difference (Final Values)
9.7
Standard Error of the Mean
5.96
95
-2.0
21.5
Superiority or Other (legacy)
OG000
OG005
Week 3: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0537
Mean Difference (Final Values)
11.6
Standard Error of the Mean
5.98
95
-0.2
23.4
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0772
Mean Difference (Final Values)
10.6
Standard Error of the Mean
5.99
95
-1.2
22.4
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1296
Mean Difference (Final Values)
8.8
Standard Error of the Mean
5.81
95
-2.6
20.3
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0140
Mean Difference (Final Values)
15.0
Standard Error of the Mean
6.06
95
3.1
27.0
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0642
Mean Difference (Final Values)
11.0
Standard Error of the Mean
5.93
95
-0.7
22.7
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0730
Mean Difference (Final Values)
10.7
Standard Error of the Mean
5.92
95
-1.0
22.3
Superiority or Other (legacy)
OG000
OG001
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0215
Mean Difference (Final Values)
13.9
Standard Error of the Mean
6.01
95
2.1
25.8
Superiority or Other (legacy)
OG000
OG002
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3785
Mean Difference (Final Values)
5.2
Standard Error of the Mean
5.84
95
-6.4
16.7
Superiority or Other (legacy)
OG000
OG003
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0089
Mean Difference (Final Values)
16.1
Standard Error of the Mean
6.12
95
4.1
28.2
Superiority or Other (legacy)
OG000
OG004
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0609
Mean Difference (Final Values)
11.2
Standard Error of the Mean
5.96
95
-0.5
23.0
Superiority or Other (legacy)
OG000
OG005
Week 5: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0064
Mean Difference (Final Values)
16.4
Standard Error of the Mean
5.95
95
4.7
28.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0241
Mean Difference (Final Values)
13.7
Standard Error of the Mean
6.01
95
1.8
25.5
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1032
Mean Difference (Final Values)
9.6
Standard Error of the Mean
5.86
95
-2.0
21.1
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0076
Mean Difference (Final Values)
16.6
Standard Error of the Mean
6.16
95
4.4
28.7
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1257
Mean Difference (Final Values)
9.2
Standard Error of the Mean
5.96
95
-2.6
20.9
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0131
Mean Difference (Final Values)
14.9
Standard Error of the Mean
5.95
95
3.2
26.6
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-9.0± 4.76
OG001-18.2± 5.05
OG002-21.1± 4.87
OG003-23.0± 5.26
OG004-17.7± 4.93
OG005-26.3± 4.89
Week 2
Title
Measurements
OG000-15.7± 4.76
OG001-25.1± 5.14
OG002-23.0± 4.81
OG003
Week 4
Title
Measurements
OG000-22.0± 4.81
OG001-18.5± 5.07
OG002-28.3± 4.76
OG003
Week 6
Title
Measurements
OG000-19.3± 4.87
OG001-29.2± 5.14
OG002-25.3± 4.81
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1824
Mean Difference (Final Values)
-9.3
Standard Error of the Mean
6.94
95
-23.0
4.4
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0767
Mean Difference (Final Values)
-12.1
Standard Error of the Mean
6.80
95
-25.5
1.3
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0492
Mean Difference (Final Values)
-14.1
Standard Error of the Mean
7.11
95
-28.1
-0.1
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2023
Mean Difference (Final Values)
-8.7
Standard Error of the Mean
6.84
95
-22.2
4.7
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0116
Mean Difference (Final Values)
-17.4
Standard Error of the Mean
6.83
95
-30.9
-3.9
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1819
Mean Difference (Final Values)
-9.4
Standard Error of the Mean
7.01
95
-23.2
4.4
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2806
Mean Difference (Final Values)
-7.3
Standard Error of the Mean
6.76
95
-20.6
6.0
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1465
Mean Difference (Final Values)
-10.4
Standard Error of the Mean
7.13
95
-24.4
3.7
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0046
Mean Difference (Final Values)
-19.6
Standard Error of the Mean
6.85
95
-33.1
-6.1
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0187
Mean Difference (Final Values)
-16.4
Standard Error of the Mean
6.92
95
-30.0
-2.8
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6128
Mean Difference (Final Values)
3.5
Standard Error of the Mean
7.00
95
-10.2
17.3
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3488
Mean Difference (Final Values)
-6.4
Standard Error of the Mean
6.76
95
-19.7
7.0
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1472
Mean Difference (Final Values)
-10.4
Standard Error of the Mean
7.17
95
-24.5
3.7
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0791
Mean Difference (Final Values)
-12.2
Standard Error of the Mean
6.89
95
-25.7
1.4
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0282
Mean Difference (Final Values)
-15.4
Standard Error of the Mean
6.97
95
-29.1
-1.7
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1623
Mean Difference (Final Values)
-9.9
Standard Error of the Mean
7.08
95
-23.9
4.0
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3739
Mean Difference (Final Values)
-6.1
Standard Error of the Mean
6.84
95
-19.6
7.4
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0517
Mean Difference (Final Values)
-14.2
Standard Error of the Mean
7.26
95
-28.5
0.1
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0815
Mean Difference (Final Values)
-12.1
Standard Error of the Mean
6.92
95
-25.8
1.5
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0031
Mean Difference (Final Values)
-20.9
Standard Error of the Mean
7.00
95
-34.7
-7.1
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-2.4± 5.39
OG0015.2± 5.72
OG002-8.6± 5.53
OG0030.7± 6.04
OG004-2.9± 5.46
OG005-9.2± 5.54
Week 2
Title
Measurements
OG000-1.5± 5.39
OG001-0.8± 5.81
OG002-11.4± 5.47
OG003
Week 4
Title
Measurements
OG000-3.2± 5.44
OG0014.4± 5.75
OG002-4.0± 5.42
OG003
Week 6
Title
Measurements
OG000-2.1± 5.50
OG0012.5± 5.81
OG002-6.6± 5.47
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3368
Mean Difference (Final Values)
7.6
Standard Error of the Mean
7.88
95
-8.0
23.1
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4232
Mean Difference (Final Values)
-6.2
Standard Error of the Mean
7.75
95
-21.5
9.1
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7082
Mean Difference (Final Values)
3.0
Standard Error of the Mean
8.09
95
-12.9
19.0
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9466
Mean Difference (Final Values)
-0.5
Standard Error of the Mean
7.70
95
-15.7
14.7
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3746
Mean Difference (Final Values)
-6.9
Standard Error of the Mean
7.72
95
-22.1
8.4
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9336
Mean Difference (Final Values)
0.7
Standard Error of the Mean
7.95
95
-15.0
16.3
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2029
Mean Difference (Final Values)
-9.8
Standard Error of the Mean
7.71
95
-25.0
5.4
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3833
Mean Difference (Final Values)
-7.1
Standard Error of the Mean
8.18
95
-23.3
9.0
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8152
Mean Difference (Final Values)
-1.8
Standard Error of the Mean
7.72
95
-17.0
13.4
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1739
Mean Difference (Final Values)
-10.7
Standard Error of the Mean
7.81
95
-26.1
4.7
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3392
Mean Difference (Final Values)
7.6
Standard Error of the Mean
7.94
95
-8.0
23.3
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9130
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
7.71
95
-16.0
14.4
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6000
Mean Difference (Final Values)
-4.3
Standard Error of the Mean
8.22
95
-20.5
11.9
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4445
Mean Difference (Final Values)
5.9
Standard Error of the Mean
7.75
95
-9.3
21.2
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9656
Mean Difference (Final Values)
-0.3
Standard Error of the Mean
7.85
95
-15.8
15.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5679
Mean Difference (Final Values)
4.6
Standard Error of the Mean
8.02
95
-11.2
20.4
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5619
Mean Difference (Final Values)
-4.5
Standard Error of the Mean
7.79
95
-19.9
10.8
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9930
Mean Difference (Final Values)
0.1
Standard Error of the Mean
8.31
95
-16.3
16.4
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6892
Mean Difference (Final Values)
3.1
Standard Error of the Mean
7.79
95
-12.2
18.5
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4928
Mean Difference (Final Values)
-5.4
Standard Error of the Mean
7.89
95
-21.0
10.1
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-7.3± 3.49
OG001-1.7± 3.72
OG002-5.3± 3.62
OG003-9.2± 3.92
OG004-8.6± 3.51
OG0051.4± 3.58
Week 2
Title
Measurements
OG000-9.1± 3.49
OG001-4.3± 3.81
OG002-8.8± 3.54
OG003
Week 4
Title
Measurements
OG000-9.9± 3.56
OG001-2.5± 3.73
OG002-8.9± 3.47
OG003
Week 6
Title
Measurements
OG000-7.4± 3.63
OG001-0.9± 3.81
OG002-4.9± 3.54
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2719
Mean Difference (Final Values)
5.6
Standard Error of the Mean
5.10
95
-4.4
15.6
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6930
Mean Difference (Final Values)
2.0
Standard Error of the Mean
5.02
95
-7.9
11.8
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7178
Mean Difference (Final Values)
-1.9
Standard Error of the Mean
5.24
95
-12.2
8.4
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8037
Mean Difference (Final Values)
-1.2
Standard Error of the Mean
4.96
95
-11.0
8.5
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0832
Mean Difference (Final Values)
8.7
Standard Error of the Mean
5.02
95
-1.2
18.6
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3554
Mean Difference (Final Values)
4.8
Standard Error of the Mean
5.17
95
-5.4
14.9
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9538
Mean Difference (Final Values)
0.3
Standard Error of the Mean
4.96
95
-9.5
10.0
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5593
Mean Difference (Final Values)
-3.1
Standard Error of the Mean
5.26
95
-13.4
7.3
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8663
Mean Difference (Final Values)
0.8
Standard Error of the Mean
4.97
95
-8.9
10.6
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1190
Mean Difference (Final Values)
8.0
Standard Error of the Mean
5.12
95
-2.1
18.1
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1544
Mean Difference (Final Values)
7.4
Standard Error of the Mean
5.15
95
-2.8
17.5
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8439
Mean Difference (Final Values)
1.0
Standard Error of the Mean
4.97
95
-8.8
10.7
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9925
Mean Difference (Final Values)
-0.0
Standard Error of the Mean
5.30
95
-10.5
10.4
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8784
Mean Difference (Final Values)
0.8
Standard Error of the Mean
5.02
95
-9.1
10.6
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8948
Mean Difference (Final Values)
0.7
Standard Error of the Mean
5.17
95
-9.5
10.8
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2197
Mean Difference (Final Values)
6.5
Standard Error of the Mean
5.26
95
-3.9
16.8
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6183
Mean Difference (Final Values)
2.5
Standard Error of the Mean
5.07
95
-7.4
12.5
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4484
Mean Difference (Final Values)
-4.1
Standard Error of the Mean
5.42
95
-14.8
6.5
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3857
Mean Difference (Final Values)
4.4
Standard Error of the Mean
5.07
95
-5.6
14.4
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8824
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
5.22
95
-11.0
9.5
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG0005.2± 5.38
OG00116.1± 5.76
OG0025.3± 5.53
OG00313.7± 6.01
OG0049.8± 5.50
OG00516.1± 5.58
Week 2
Title
Measurements
OG00015.6± 5.38
OG00131.0± 5.87
OG00219.6± 5.45
OG003
Week 4
Title
Measurements
OG00015.6± 5.45
OG00123.9± 5.78
OG00220.8± 5.38
OG003
Week 6
Title
Measurements
OG00016.8± 5.54
OG00134.6± 5.87
OG00227.0± 5.45
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1673
Mean Difference (Final Values)
10.9
Standard Error of the Mean
7.87
95
-4.6
26.4
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.9839
Mean Difference (Final Values)
0.2
Standard Error of the Mean
7.71
95
-15.0
15.3
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2905
Mean Difference (Final Values)
8.5
Standard Error of the Mean
8.06
95
-7.3
24.4
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5513
Mean Difference (Final Values)
4.6
Standard Error of the Mean
7.69
95
-10.6
19.7
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1589
Mean Difference (Final Values)
11.0
Standard Error of the Mean
7.77
95
-4.3
26.3
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0541
Mean Difference (Final Values)
15.4
Standard Error of the Mean
7.95
95
-0.3
31.0
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5987
Mean Difference (Final Values)
4.0
Standard Error of the Mean
7.66
95
-11.0
19.1
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4372
Mean Difference (Final Values)
6.3
Standard Error of the Mean
8.10
95
-9.6
22.2
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8336
Mean Difference (Final Values)
-1.6
Standard Error of the Mean
7.71
95
-16.8
13.6
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0804
Mean Difference (Final Values)
13.9
Standard Error of the Mean
7.90
95
-1.7
29.4
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2985
Mean Difference (Final Values)
8.3
Standard Error of the Mean
7.94
95
-7.4
23.9
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4991
Mean Difference (Final Values)
5.2
Standard Error of the Mean
7.66
95
-9.9
20.3
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2675
Mean Difference (Final Values)
9.1
Standard Error of the Mean
8.15
95
-7.0
25.1
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1593
Mean Difference (Final Values)
11.0
Standard Error of the Mean
7.77
95
-4.3
26.3
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0179
Mean Difference (Final Values)
18.9
Standard Error of the Mean
7.96
95
3.3
34.6
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0281
Mean Difference (Final Values)
17.8
Standard Error of the Mean
8.06
95
1.9
33.7
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1883
Mean Difference (Final Values)
10.3
Standard Error of the Mean
7.77
95
-5.0
25.5
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2300
Mean Difference (Final Values)
10.0
Standard Error of the Mean
8.28
95
-6.3
26.3
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7575
Mean Difference (Final Values)
2.4
Standard Error of the Mean
7.82
95
-13.0
17.8
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0757
Mean Difference (Final Values)
14.3
Standard Error of the Mean
8.02
95
-1.5
30.1
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-7.4± 4.02
OG001-13.8± 4.29
OG002-9.8± 4.12
OG003-14.3± 4.46
OG004-11.2± 4.07
OG005-10.7± 4.14
Week 2
Title
Measurements
OG000-13.9± 4.02
OG001-18.2± 4.36
OG002-11.1± 4.07
OG003
Week 4
Title
Measurements
OG000-14.0± 4.07
OG001-20.4± 4.30
OG002-11.8± 4.02
OG003
Week 6
Title
Measurements
OG000-11.7± 4.12
OG001-26.3± 4.36
OG002-14.8± 4.07
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2817
Mean Difference (Final Values)
-6.4
Standard Error of the Mean
5.89
95
-18.0
5.2
Superiority or Other (legacy)
OG000
OG002
Week 1: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6796
Mean Difference (Final Values)
-2.4
Standard Error of the Mean
5.76
95
-13.7
9.0
Superiority or Other (legacy)
OG000
OG003
Week 1: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2505
Mean Difference (Final Values)
-6.9
Standard Error of the Mean
6.01
95
-18.8
4.9
Superiority or Other (legacy)
OG000
OG004
Week 1: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5102
Mean Difference (Final Values)
-3.8
Standard Error of the Mean
5.73
95
-15.1
7.5
Superiority or Other (legacy)
OG000
OG005
Week 1: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5706
Mean Difference (Final Values)
-3.3
Standard Error of the Mean
5.78
95
-14.7
8.1
Superiority or Other (legacy)
OG000
OG001
Week 2: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4708
Mean Difference (Final Values)
-4.3
Standard Error of the Mean
5.95
95
-16.0
7.4
Superiority or Other (legacy)
OG000
OG002
Week 2: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6202
Mean Difference (Final Values)
2.8
Standard Error of the Mean
5.72
95
-8.4
14.1
Superiority or Other (legacy)
OG000
OG003
Week 2: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4177
Mean Difference (Final Values)
-4.9
Standard Error of the Mean
6.04
95
-16.8
7.0
Superiority or Other (legacy)
OG000
OG004
Week 2: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6509
Mean Difference (Final Values)
2.6
Standard Error of the Mean
5.75
95
-8.7
13.9
Superiority or Other (legacy)
OG000
OG005
Week 2: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8273
Mean Difference (Final Values)
1.3
Standard Error of the Mean
5.86
95
-10.3
12.8
Superiority or Other (legacy)
OG000
OG001
Week 4: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2842
Mean Difference (Final Values)
-6.4
Standard Error of the Mean
5.94
95
-18.1
5.3
Superiority or Other (legacy)
OG000
OG002
Week 4: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7041
Mean Difference (Final Values)
2.2
Standard Error of the Mean
5.72
95
-9.1
13.5
Superiority or Other (legacy)
OG000
OG003
Week 4: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7216
Mean Difference (Final Values)
-2.2
Standard Error of the Mean
6.07
95
-14.1
9.8
Superiority or Other (legacy)
OG000
OG004
Week 4: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6188
Mean Difference (Final Values)
-2.9
Standard Error of the Mean
5.78
95
-14.3
8.5
Superiority or Other (legacy)
OG000
OG005
Week 4: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8096
Mean Difference (Final Values)
1.4
Standard Error of the Mean
5.90
95
-10.2
13.0
Superiority or Other (legacy)
OG000
OG001
Week 6: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0157
Mean Difference (Final Values)
-14.6
Standard Error of the Mean
6.01
95
-26.5
-2.8
Superiority or Other (legacy)
OG000
OG002
Week 6: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6007
Mean Difference (Final Values)
-3.0
Standard Error of the Mean
5.79
95
-14.4
8.4
Superiority or Other (legacy)
OG000
OG003
Week 6: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1057
Mean Difference (Final Values)
-10.0
Standard Error of the Mean
6.15
95
-22.1
2.1
Superiority or Other (legacy)
OG000
OG004
Week 6: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7764
Mean Difference (Final Values)
-1.7
Standard Error of the Mean
5.81
95
-13.1
9.8
Superiority or Other (legacy)
OG000
OG005
Week 6: contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7146
Mean Difference (Final Values)
-2.2
Standard Error of the Mean
5.93
95
-13.9
9.5
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG0000.4± 0.21
OG0010.7± 0.22
OG0020.5± 0.22
OG0030.9± 0.23
OG0040.4± 0.21
OG0050.7± 0.22
Week 2
Title
Measurements
OG0000.5± 0.21
OG0010.8± 0.23
OG0020.6± 0.21
OG003
Week 4
Title
Measurements
OG0000.6± 0.21
OG0011.0± 0.22
OG0020.7± 0.21
OG003
Week 6
Title
Measurements
OG0000.6± 0.22
OG0010.9± 0.23
OG0020.7± 0.21
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2978
Mean Difference (Final Values)
0.3
Standard Error of the Mean
0.31
95
-0.3
0.9
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7242
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0773
Mean Difference (Final Values)
0.6
Standard Error of the Mean
0.32
95
-0.1
1.2
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7831
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3291
Mean Difference (Final Values)
0.3
Standard Error of the Mean
0.30
95
-0.3
0.9
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3692
Mean Difference (Final Values)
0.3
Standard Error of the Mean
0.31
95
-0.3
0.9
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7614
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0355
Mean Difference (Final Values)
0.7
Standard Error of the Mean
0.32
95
0.0
1.3
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5068
Mean Difference (Final Values)
0.2
Standard Error of the Mean
0.30
95
-0.4
0.8
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0561
Mean Difference (Final Values)
0.6
Standard Error of the Mean
0.31
95
-0.0
1.2
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2223
Mean Difference (Final Values)
0.4
Standard Error of the Mean
0.31
95
-0.2
1.0
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6791
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0188
Mean Difference (Final Values)
0.8
Standard Error of the Mean
0.32
95
0.1
1.4
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1314
Mean Difference (Final Values)
0.5
Standard Error of the Mean
0.30
95
-0.1
1.1
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0900
Mean Difference (Final Values)
0.5
Standard Error of the Mean
0.31
95
-0.1
1.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4144
Mean Difference (Final Values)
0.3
Standard Error of the Mean
0.31
95
-0.4
0.9
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7699
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0406
Mean Difference (Final Values)
0.7
Standard Error of the Mean
0.32
95
0.0
1.3
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.7574
Mean Difference (Final Values)
0.1
Standard Error of the Mean
0.30
95
-0.5
0.7
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0554
Mean Difference (Final Values)
0.6
Standard Error of the Mean
0.31
95
-0.0
1.2
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-9.2± 3.67
OG001-12.5± 3.91
OG002-10.4± 3.75
OG003-14.9± 4.06
OG004-13.9± 3.77
OG005-16.2± 3.77
Week 2
Title
Measurements
OG000-14.8± 3.67
OG001-22.0± 3.97
OG002-15.7± 3.71
OG003
Week 4
Title
Measurements
OG000-17.2± 3.71
OG001-17.9± 3.92
OG002-19.6± 3.67
OG003
Week 6
Title
Measurements
OG000-15.5± 3.76
OG001-25.0± 3.97
OG002-21.1± 3.71
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5409
Mean Difference (Final Values)
-3.3
Standard Error of the Mean
5.36
95
-13.8
7.3
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8230
Mean Difference (Final Values)
-1.2
Standard Error of the Mean
5.25
95
-11.5
9.2
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2958
Mean Difference (Final Values)
-5.7
Standard Error of the Mean
5.48
95
-16.5
5.1
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3708
Mean Difference (Final Values)
-4.7
Standard Error of the Mean
5.27
95
-15.1
5.7
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1853
Mean Difference (Final Values)
-7.0
Standard Error of the Mean
5.27
95
-17.4
3.4
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1834
Mean Difference (Final Values)
-7.2
Standard Error of the Mean
5.41
95
-17.9
3.4
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8711
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
5.22
95
-11.1
9.4
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3252
Mean Difference (Final Values)
-5.4
Standard Error of the Mean
5.50
95
-16.3
5.4
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3205
Mean Difference (Final Values)
-5.3
Standard Error of the Mean
5.28
95
-15.7
5.1
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0837
Mean Difference (Final Values)
-9.3
Standard Error of the Mean
5.34
95
-19.8
1.2
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8895
Mean Difference (Final Values)
-0.8
Standard Error of the Mean
5.40
95
-11.4
9.9
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.6469
Mean Difference (Final Values)
-2.4
Standard Error of the Mean
5.22
95
-12.7
7.9
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2687
Mean Difference (Final Values)
-6.1
Standard Error of the Mean
5.53
95
-17.0
4.8
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1757
Mean Difference (Final Values)
-7.2
Standard Error of the Mean
5.31
95
-17.7
3.3
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0306
Mean Difference (Final Values)
-11.7
Standard Error of the Mean
5.38
95
-22.3
-1.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0857
Mean Difference (Final Values)
-9.4
Standard Error of the Mean
5.47
95
-20.2
1.3
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2932
Mean Difference (Final Values)
-5.6
Standard Error of the Mean
5.28
95
-16.0
4.8
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0613
Mean Difference (Final Values)
-10.5
Standard Error of the Mean
5.60
95
-21.6
0.5
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5431
Mean Difference (Final Values)
-3.3
Standard Error of the Mean
5.34
95
-13.8
7.3
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0262
Mean Difference (Final Values)
-12.1
Standard Error of the Mean
5.41
95
-22.7
-1.4
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG000-8.1± 3.73
OG001-15.9± 3.96
OG002-14.2± 3.81
OG003-17.8± 4.12
OG004-14.4± 3.84
OG005-18.8± 3.83
Week 2
Title
Measurements
OG000-15.5± 3.73
OG001-23.5± 4.03
OG002-19.0± 3.76
OG003
Week 4
Title
Measurements
OG000-18.2± 3.77
OG001-19.3± 3.98
OG002-22.0± 3.73
OG003
Week 6
Title
Measurements
OG000-16.8± 3.81
OG001-27.5± 4.03
OG002-22.2± 3.76
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1547
Mean Difference (Final Values)
-7.8
Standard Error of the Mean
5.44
95
-18.5
3.0
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2532
Mean Difference (Final Values)
-6.1
Standard Error of the Mean
5.33
95
-16.6
4.4
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0848
Mean Difference (Final Values)
-9.6
Standard Error of the Mean
5.56
95
-20.6
1.3
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2424
Mean Difference (Final Values)
-6.3
Standard Error of the Mean
5.36
95
-16.8
4.3
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0470
Mean Difference (Final Values)
-10.7
Standard Error of the Mean
5.35
95
-21.2
-0.1
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1494
Mean Difference (Final Values)
-7.9
Standard Error of the Mean
5.49
95
-18.8
2.9
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.5081
Mean Difference (Final Values)
-3.5
Standard Error of the Mean
5.30
95
-13.9
6.9
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2141
Mean Difference (Final Values)
-7.0
Standard Error of the Mean
5.58
95
-17.9
4.0
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1484
Mean Difference (Final Values)
-7.8
Standard Error of the Mean
5.37
95
-18.4
2.8
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0963
Mean Difference (Final Values)
-9.0
Standard Error of the Mean
5.42
95
-19.7
1.6
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.8519
Mean Difference (Final Values)
-1.0
Standard Error of the Mean
5.48
95
-11.8
9.8
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.4770
Mean Difference (Final Values)
-3.8
Standard Error of the Mean
5.30
95
-14.2
6.7
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.2166
Mean Difference (Final Values)
-6.9
Standard Error of the Mean
5.61
95
-18.0
4.1
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.1062
Mean Difference (Final Values)
-8.8
Standard Error of the Mean
5.40
95
-19.4
1.9
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0475
Mean Difference (Final Values)
-10.9
Standard Error of the Mean
5.45
95
-21.6
-0.1
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0537
Mean Difference (Final Values)
-10.7
Standard Error of the Mean
5.54
95
-21.7
0.2
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3153
Mean Difference (Final Values)
-5.4
Standard Error of the Mean
5.35
95
-15.9
5.2
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0424
Mean Difference (Final Values)
-11.6
Standard Error of the Mean
5.68
95
-22.8
-0.4
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.3077
Mean Difference (Final Values)
-5.5
Standard Error of the Mean
5.42
95
-16.2
5.1
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs placebo. Repeated measures model used fixed effects of treatment, geographic region, week and treatment by week interaction. Baseline score is included as a covariate. Additionally, the model includes subject as a repeated measurement block within which the covariance structure is assumed to be compound symmetric (CS).
Mixed Models Analysis
0.0224
Mean Difference (Final Values)
-12.6
Standard Error of the Mean
5.48
95
-23.4
-1.8
Superiority or Other (legacy)
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Week 1
Title
Measurements
OG0006
OG00110
OG0027
OG0039
OG0046
OG00511
Week 2
Title
Measurements
OG0008
OG0016
OG00211
OG003
Week 4
Title
Measurements
OG00011
OG00112
OG00211
OG003
Week 6
Title
Measurements
OG00012
OG00111
OG00211
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Week 1: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.0646
Odds Ratio (OR)
3.7
Standard Error of the Mean
2.65
95
0.9
15.0
Superiority or Other (legacy)
OG000
OG002
Week 1: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.2947
Odds Ratio (OR)
2.2
Standard Error of the Mean
1.58
95
0.5
9.1
Superiority or Other (legacy)
OG000
OG003
Week 1: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.0249
Odds Ratio (OR)
4.6
Standard Error of the Mean
3.10
95
1.2
17.2
Superiority or Other (legacy)
OG000
OG004
Week 1: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.7671
Odds Ratio (OR)
1.3
Standard Error of the Mean
0.99
95
0.3
5.9
Superiority or Other (legacy)
OG000
OG005
Week 1: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.0169
Odds Ratio (OR)
4.6
Standard Error of the Mean
2.90
95
1.3
15.9
Superiority or Other (legacy)
OG000
OG001
Week 2: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.9569
Odds Ratio (OR)
1.0
Standard Error of the Mean
0.74
95
0.2
4.3
Superiority or Other (legacy)
OG000
OG002
Week 2: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means.Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.0711
Odds Ratio (OR)
3.2
Standard Error of the Mean
2.07
95
0.9
11.4
Superiority or Other (legacy)
OG000
OG003
Week 2: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.1073
Odds Ratio (OR)
2.8
Standard Error of the Mean
1.85
95
0.8
10.2
Superiority or Other (legacy)
OG000
OG004
Week 2: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.1583
Odds Ratio (OR)
2.4
Standard Error of the Mean
1.48
95
0.7
8.1
Superiority or Other (legacy)
OG000
OG005
Week 2: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.0385
Odds Ratio (OR)
4.1
Standard Error of the Mean
2.80
95
1.1
15.6
Superiority or Other (legacy)
OG000
OG001
Week 4: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.4923
Odds Ratio (OR)
1.6
Standard Error of the Mean
1.09
95
0.4
6.1
Superiority or Other (legacy)
OG000
OG002
Week 4: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.7169
Odds Ratio (OR)
1.3
Standard Error of the Mean
0.80
95
0.4
4.4
Superiority or Other (legacy)
OG000
OG003
Week 4: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.4156
Odds Ratio (OR)
1.7
Standard Error of the Mean
1.12
95
0.5
6.2
Superiority or Other (legacy)
OG000
OG004
Week 4: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.4165
Odds Ratio (OR)
1.7
Standard Error of the Mean
1.04
95
0.5
5.6
Superiority or Other (legacy)
OG000
OG005
Week 4: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.4673
Odds Ratio (OR)
1.6
Standard Error of the Mean
1.08
95
0.4
6.0
Superiority or Other (legacy)
OG000
OG001
Week 6: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.9855
Odds Ratio (OR)
1.0
Standard Error of the Mean
0.72
95
0.2
4.1
Superiority or Other (legacy)
OG000
OG002
Week 6: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.9566
Odds Ratio (OR)
1.0
Standard Error of the Mean
0.61
95
0.3
3.3
Superiority or Other (legacy)
OG000
OG003
Week 6: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.4632
Odds Ratio (OR)
1.7
Standard Error of the Mean
1.17
95
0.4
6.6
Superiority or Other (legacy)
OG000
OG004
Week 6: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.2042
Odds Ratio (OR)
0.4
Standard Error of the Mean
0.29
95
0.1
1.6
Superiority or Other (legacy)
OG000
OG005
Week 6: Contrast of treatment vs. placebo. Differences in proportions were obtained using LS means. Repeated measures logistic regression model used fixed effects including treatment, geographic region, week, and the treatment by week interaction. The within-subject covariance structure was modeled as compound sysmetric.
Regression, Logistic
0.3382
Odds Ratio (OR)
1.9
Standard Error of the Mean
1.34
95
0.5
7.5
Superiority or Other (legacy)
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Title
Measurements
OG00015.0± 3.71
OG00119.6± 3.87
OG00222.4± 3.55
OG00320.8± 3.94
OG00415.9± 3.63
OG00520.5± 3.74
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Analysis of covariance of change from baseline; LS Mean, standard error, 95% CI and P-value are from an analysis of covariance (ANCOVA), with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3932
Mean Difference (Final Values)
4.6
95
-6.0
15.2
Superiority or Other (legacy)
OG000
OG002
Analysis of covariance of change from baseline; LS Mean, standard error, 95% CI and P-value are from an analysis of covariance (ANCOVA), with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1585
Mean Difference (Final Values)
7.3
95
-2.9
17.5
Superiority or Other (legacy)
OG000
OG003
Analysis of covariance of change from baseline; LS Mean, standard error, 95% CI and P-value are from an analysis of covariance (ANCOVA), with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.2850
Mean Difference (Final Values)
5.8
95
-4.9
16.5
Superiority or Other (legacy)
OG000
OG004
Analysis of covariance of change from baseline; LS Mean, standard error, 95% CI and P-value are from an analysis of covariance (ANCOVA), with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8645
Mean Difference (Final Values)
0.9
95
-9.4
11.1
Superiority or Other (legacy)
OG000
OG005
Analysis of covariance of change from baseline; LS Mean, standard error, 95% CI and P-value are from an analysis of covariance (ANCOVA), with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3031
Mean Difference (Final Values)
5.4
95
-5.0
15.8
Superiority or Other (legacy)
OG003
Pregabalin 150 mg
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Physical Functioning
Title
Measurements
OG0003.6± 3.50
OG0010.5± 3.71
OG0022.4± 3.42
OG003-0.4± 3.93
OG0042.9± 3.52
OG0053.6± 3.62
Role-Physical
Title
Measurements
OG0001.1± 4.24
OG0017.0± 4.49
OG0027.5± 4.14
OG003
Bodily Pain
Title
Measurements
OG0006.9± 4.16
OG00115.8± 4.41
OG00212.9± 4.07
OG003
General Health
Title
Measurements
OG0006.5± 2.81
OG0015.2± 3.05
OG0024.0± 2.75
OG003
Vitality
Title
Measurements
OG0007.4± 3.98
OG00111.1± 4.18
OG0029.9± 3.86
OG003
Social Functioning
Title
Measurements
OG0007.8± 3.98
OG0018.3± 4.20
OG0024.8± 3.88
OG003
Role-Emotional
Title
Measurements
OG000-2.1± 4.16
OG0016.7± 4.38
OG0027.8± 4.05
OG003
Mental Health
Title
Measurements
OG0002.9± 3.49
OG0011.0± 3.68
OG0023.6± 3.43
OG003
Summary Physical Score
Title
Measurements
OG0004.5± 2.83
OG0017.4± 3.02
OG0026.7± 2.77
OG003
Summary Emotional Score
Title
Measurements
OG0003.7± 3.33
OG0016.9± 3.51
OG0026.7± 3.24
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
Physical Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5384
Mean Difference (Final Values)
-3.1
95
-13.2
7.0
Superiority or Other (legacy)
OG000
OG002
Physical Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8015
Mean Difference (Final Values)
-1.2
95
-10.9
8.5
Superiority or Other (legacy)
OG000
OG003
Physical Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.4429
Mean Difference (Final Values)
-4.1
95
-14.5
6.4
Superiority or Other (legacy)
OG000
OG004
Physical Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8860
Mean Difference (Final Values)
-0.7
95
-10.5
9.1
Superiority or Other (legacy)
OG000
OG005
Physical Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.9963
Mean Difference (Final Values)
-0.0
95
-10.0
9.9
Superiority or Other (legacy)
OG000
OG001
Role-Physical: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3421
Mean Difference (Final Values)
5.9
95
-6.3
18.1
Superiority or Other (legacy)
OG000
OG002
Role-Physical: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.2849
Mean Difference (Final Values)
6.4
95
-5.4
18.1
Superiority or Other (legacy)
OG000
OG003
Role-Physical: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3058
Mean Difference (Final Values)
6.6
95
-6.1
19.2
Superiority or Other (legacy)
OG000
OG004
Role-Physical: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.9604
Mean Difference (Final Values)
-0.3
95
-12.1
11.5
Superiority or Other (legacy)
OG000
OG005
Role-Physical: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1661
Mean Difference (Final Values)
8.5
95
-3.6
20.6
Superiority or Other (legacy)
OG000
OG001
Bodily Pain: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1441
Mean Difference (Final Values)
8.9
95
-3.1
20.9
Superiority or Other (legacy)
OG000
OG002
Bodily Pain: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3076
Mean Difference (Final Values)
6.0
95
-5.6
17.5
Superiority or Other (legacy)
OG000
OG003
Bodily Pain: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1209
Mean Difference (Final Values)
10.0
95
-2.7
22.7
Superiority or Other (legacy)
OG000
OG004
Bodily Pain: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.2791
Mean Difference (Final Values)
6.4
95
-5.3
18.0
Superiority or Other (legacy)
OG000
OG005
Bodily Pain: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0644
Mean Difference (Final Values)
11.2
95
-0.7
23.0
Superiority or Other (legacy)
OG000
OG001
General Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.7544
Mean Difference (Final Values)
-1.3
95
-9.5
6.9
Superiority or Other (legacy)
OG000
OG002
General Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5142
Mean Difference (Final Values)
-2.6
95
-10.3
5.2
Superiority or Other (legacy)
OG000
OG003
General Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8158
Mean Difference (Final Values)
1.0
95
-7.4
9.4
Superiority or Other (legacy)
OG000
OG004
General Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.4599
Mean Difference (Final Values)
-2.9
95
-10.8
4.9
Superiority or Other (legacy)
OG000
OG005
General Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8636
Mean Difference (Final Values)
-0.7
95
-8.7
7.3
Superiority or Other (legacy)
OG000
OG001
Vitality: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5281
Mean Difference (Final Values)
3.7
95
-7.8
15.1
Superiority or Other (legacy)
OG000
OG002
Vitality: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.6566
Mean Difference (Final Values)
2.5
95
-8.5
13.5
Superiority or Other (legacy)
OG000
OG003
Vitality: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0677
Mean Difference (Final Values)
11.1
95
-0.8
23.0
Superiority or Other (legacy)
OG000
OG004
Vitality: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.4443
Mean Difference (Final Values)
4.3
95
-6.8
15.4
Superiority or Other (legacy)
OG000
OG005
Vitality: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.2543
Mean Difference (Final Values)
6.5
95
-4.7
17.7
Superiority or Other (legacy)
OG000
OG001
Social Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.9416
Mean Difference (Final Values)
0.4
95
-11.0
11.9
Superiority or Other (legacy)
OG000
OG002
Social Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5824
Mean Difference (Final Values)
-3.1
95
-14.1
7.9
Superiority or Other (legacy)
OG000
OG003
Social Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5668
Mean Difference (Final Values)
-3.4
95
-15.3
8.4
Superiority or Other (legacy)
OG000
OG004
Social Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.7769
Mean Difference (Final Values)
1.6
95
-9.6
12.8
Superiority or Other (legacy)
OG000
OG005
Social Functioning: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1753
Mean Difference (Final Values)
7.8
95
-3.5
19.1
Superiority or Other (legacy)
OG000
OG001
Role-Emotional: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1508
Mean Difference (Final Values)
8.7
95
-3.2
20.7
Superiority or Other (legacy)
OG000
OG002
Role-Emotional: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0916
Mean Difference (Final Values)
9.9
95
-1.6
21.4
Superiority or Other (legacy)
OG000
OG003
Role-Emotional: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.6222
Mean Difference (Final Values)
3.1
95
-9.2
15.4
Superiority or Other (legacy)
OG000
OG004
Role-Emotional: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0850
Mean Difference (Final Values)
10.2
95
-1.4
21.8
Superiority or Other (legacy)
OG000
OG005
Role-Emotional: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0154
Mean Difference (Final Values)
14.8
95
2.9
26.7
Superiority or Other (legacy)
OG000
OG001
Mental Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.7201
Mean Difference (Final Values)
-1.8
95
-11.9
8.2
Superiority or Other (legacy)
OG000
OG002
Mental Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8875
Mean Difference (Final Values)
0.7
95
-9.1
10.5
Superiority or Other (legacy)
OG000
OG003
Mental Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3735
Mean Difference (Final Values)
4.7
95
-5.7
15.1
Superiority or Other (legacy)
OG000
OG004
Mental Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.8621
Mean Difference (Final Values)
0.9
95
-8.9
10.6
Superiority or Other (legacy)
OG000
OG005
Mental Health: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.1203
Mean Difference (Final Values)
7.9
95
-2.1
17.8
Superiority or Other (legacy)
OG000
OG001
Summary Physical Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.4966
Mean Difference (Final Values)
2.8
95
-5.4
11.0
Superiority or Other (legacy)
OG000
OG002
Summary Physical Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5776
Mean Difference (Final Values)
2.2
95
-5.6
10.1
Superiority or Other (legacy)
OG000
OG003
Summary Physical Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3955
Mean Difference (Final Values)
3.7
95
-4.9
12.3
Superiority or Other (legacy)
OG000
OG004
Summary Physical Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.7994
Mean Difference (Final Values)
1.0
95
-6.9
9.0
Superiority or Other (legacy)
OG000
OG005
Summary Physical Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.2073
Mean Difference (Final Values)
5.2
95
-2.9
13.2
Superiority or Other (legacy)
OG000
OG001
Summary Emotional Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5148
Mean Difference (Final Values)
3.2
95
-6.4
12.8
Superiority or Other (legacy)
OG000
OG002
Summary Emotional Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.5255
Mean Difference (Final Values)
3.0
95
-6.3
12.2
Superiority or Other (legacy)
OG000
OG003
Summary Emotional Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3793
Mean Difference (Final Values)
4.4
95
-5.5
14.4
Superiority or Other (legacy)
OG000
OG004
Summary Emotional Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.3120
Mean Difference (Final Values)
4.8
95
-4.5
14.1
Superiority or Other (legacy)
OG000
OG005
Summary Emotional Score: Least Squares mean difference. LS Mean, Std. Error, 95% CI and P-value are from an analysis of covariance (ANCOVA) with treatment and geographic region as main effects and baseline value as covariate in the model.
ANCOVA
0.0442
Mean Difference (Final Values)
9.7
95
0.3
19.2
Superiority or Other (legacy)
Single daily 150 mg oral dose. Dose was escalated from 75 mg/day after Day 3.
OG004
Pregabalin 300 mg
Single daily 300 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), and 150 mg/day (Days 4-7).
OG005
Pregabalin 450 mg
Single daily 450 mg oral dose. Dose was escalated from 75 mg/day (Days 1-3), 150 mg/day (Days 4-7), and 300 mg/day (Days 8-11).
Units
Counts
Participants
OG00023
OG00122
OG00223
OG00322
OG00424
OG00523
Title
Denominators
Categories
Baseline: Much Worse than 1 Year Ago
Title
Measurements
OG0000
OG0013
OG0021
OG0032
OG0043
OG0052
Baseline: Somewhat Worse than 1 Year Ago
Title
Measurements
OG0004
OG0016
OG0023
OG003
Baseline: About the Same as 1 Year Ago
Title
Measurements
OG00015
OG0019
OG00215
OG003
Baseline: Somewhat Better than 1 Year Ago
Title
Measurements
OG0002
OG0011
OG0023
OG003
Baseline: Much Better than 1 Year Ago
Title
Measurements
OG0001
OG0011
OG0021
OG003
Week 6: Much Worse than 1 Year Ago
Title
Measurements
OG0001
OG0010
OG0020
OG003
Week 6: Somewhat Worse than 1 Year Ago
Title
Measurements
OG0002
OG0013
OG0022
OG003
Week 6: About the Same as 1 Year Ago
Title
Measurements
OG00011
OG00112
OG00210
OG003
Week 6: Somewhat Better than 1 Year Ago
Title
Measurements
OG0004
OG0012
OG0024
OG003
Week 6: Much Better than 1 Year Ago
Title
Measurements
OG0003
OG0012
OG0026
OG003
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG000
OG001
CHM test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.4452
95
Superiority or Other (legacy)
OG000
OG002
CHM test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.4342
95
Superiority or Other (legacy)
OG000
OG003
CHM test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.0942
95
Superiority or Other (legacy)
OG000
OG004
CHM test for difference; p-value was adjusted for geographic region at each visit.
Cochran-Mantel-Haenszel
0.1873
95
Superiority or Other (legacy)
OG000
OG005
CHM test for difference; p-value was adjusted for geographic region at each visit.